Peter G Rose1, Haider Mahdi, Amelia Jernigan, Bin Yang. 1. *Division of Gynecologic Oncology, Cleveland Clinic; †Division of Gynecologic Oncology, MetroHealth Medical Center; and ‡Department of Molecular Pathology, Cleveland Clinic, Cleveland, OH.
Abstract
OBJECTIVES: The aim of this study was to evaluate the antitumor activity of bevacizumab in low-grade serous ovarian carcinoma (LGSOC). METHODS: We retrospectively identified patients with LGSOC treated with bevacizumab. RESULTS: Twelve patients with LGSOC who received bevacizumab were identified. Eleven patients received bevacizumab alone. Only 1 (8.3%) of 12 patients had evidence of a partial response. Ten (90.9%) of the 11 patients were progression free at 6 months. All but 1 patient who received only 2 courses before treatment interruption had a progression-free survival (PFS) of greater than 6 months. The median PFS was 48 months (range, 5-123+ months). Three of the patients reported in this series had extended disease stabilization that lasted for 123+, 48, and 15+ months after progression-free intervals on prior chemotherapy regimens of 2.5, 4, and 7 months, respectively. The median overall survival was not reached at a median follow-up of 32 months, with only 1 of the 12 patients dying of disease. CONCLUSIONS: In our series, in patients with LGSOC treated primarily with bevacizumab, primarily as a single agent, a low response rate but very long PFS is observed. In addition, patients have had secondary PFS durations that exceeded their prior PFS, which is a sign of anticancer activity.
OBJECTIVES: The aim of this study was to evaluate the antitumor activity of bevacizumab in low-grade serous ovarian carcinoma (LGSOC). METHODS: We retrospectively identified patients with LGSOC treated with bevacizumab. RESULTS: Twelve patients with LGSOC who received bevacizumab were identified. Eleven patients received bevacizumab alone. Only 1 (8.3%) of 12 patients had evidence of a partial response. Ten (90.9%) of the 11 patients were progression free at 6 months. All but 1 patient who received only 2 courses before treatment interruption had a progression-free survival (PFS) of greater than 6 months. The median PFS was 48 months (range, 5-123+ months). Three of the patients reported in this series had extended disease stabilization that lasted for 123+, 48, and 15+ months after progression-free intervals on prior chemotherapy regimens of 2.5, 4, and 7 months, respectively. The median overall survival was not reached at a median follow-up of 32 months, with only 1 of the 12 patients dying of disease. CONCLUSIONS: In our series, in patients with LGSOC treated primarily with bevacizumab, primarily as a single agent, a low response rate but very long PFS is observed. In addition, patients have had secondary PFS durations that exceeded their prior PFS, which is a sign of anticancer activity.
Authors: Heather J Dalton; Nicole D Fleming; Charlotte C Sun; Priya Bhosale; Kathleen M Schmeler; David M Gershenson Journal: Gynecol Oncol Date: 2017-01-27 Impact factor: 5.482
Authors: Allison Gockley; Alexander Melamed; Amy J Bregar; Joel T Clemmer; Michael Birrer; John O Schorge; Marcela G Del Carmen; J Alejandro Rauh-Hain Journal: Obstet Gynecol Date: 2017-03 Impact factor: 7.661